Physician profile
Katherine Ringstad
NPI 1023663168
$2,540.40
in general payments reported to CMS, 2019-2025
18 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,711 · 2024: $726 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $595.97 | 2023-2025 | |
| Novo Nordisk INC | $366.13 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $301.09 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $249.82 | 2023-2025 | |
| Glaxosmithkline, LLC. | $226.37 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $180.98 | 2023-2024 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $95.80 | 2023-2024 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $93.46 | 2023 | |
| Exact Sciences Corporation | $87.85 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.02 | 2023-2025 | Xifaxan, Trulance |
| Currax Pharmaceuticals LLC | $60.51 | 2023 | Contrave, Onzetra Xsail, Nexlizet |
| Janssen Pharmaceuticals, INC | $53.65 | 2023-2024 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.47 | 2023-2024 | Jardiance, Tradjenta, Synjardy |
| Daiichi Sankyo INC. | $39.94 | 2023 | Injectafer |
| Corium, LLC | $18.18 | 2023 | Azstarys |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $17.50 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $16.25 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $14.41 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Ringstad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.